Meyer, T., Fox, R., Ma, Y. T., Ross, P. J., James, M. W., Sturgess, R., Stubbs, C., Stocken, D. D., Wall, L., Watkinson, A., Hacking, N., Evans, T. R. J., Collins, P., Hubner, R. A., Cunningham, D., Primrose, J. N., Johnson, P. J., & Palmer, D. H. (2017). sorafenib in combination with transarterial chemoembolisation in patients with unresectable hepatocellular carcinoma (TACE 2): a randomised placebo-controlled, double-blind, phase 3 trial. Lancet gastroenterology and hepatology, 2, 565–575. http://access.bl.uk/ark:/81055/vdc_100047555227.0x000009